All 1 tracked stories fall under one category: market-trends. Atea Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 5 original sources per story, versus 2.8 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about BBOT
All 1 tracked stories fall under one category: market-trends. Atea Pharmaceuticals is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 5 original sources per story, versus 2.8 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 5.8. BBOT appears in 1 tracked Healthcare story from March 5, 2026.
Stories tracked
1
Sources per story
5
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 25 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering BBOT. Shared-story counts are live from our verified record — not editorial picks.
Atea Pharmaceuticals and Profound Medical headlined a series of Q4 2025 earnings reports, highlighting a shift toward commercial scaling in medical devices and late-stage clinical milestones in biotech. These results underscore a sector-wide focus on capital preservation and high-margin recurring revenue models.